Saraiva, "Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy
: ocular synthesis of mutant transthyretin," Amyloid, vol.
(NYSE: PFE) has published a new interim analysis of long-term data from four studies indicating that treatment with tafamidis is associated with delay in disease progression in patients with hereditary transthyretin amyloid polyneuropathy
(TTR-FAP) and was well tolerated, with no unexpected side effects, the company said.
We present the first case of familial amyloid polyneuropathy
(FAP) type IV in an Iranian woman with severe involvement of multiple cranial nerves, peripheral limb neuropathy, and orthostatic hypotension.
This report provides comprehensive information on the therapeutic development for Familial Amyloid Polyneuropathy
(Transthyretin Amyloidosis, Corino de Andrade's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Clinical and genetic analysis of three families with familiar amyloid polyneuropathy
. Chin Med Sci J 2008;23:230-3.
Changes in renal function in patients with familial amyloid polyneuropathy
treated with orthotopic liver transplantation.
Surgeons will transplant part of the liver of a healthy 45-year-old man into his 42-year-old wife from Nagano who is suffering from a metabolic disorder known as familial amyloid polyneuropathy
(FAP), doctors said.
According to the transplant team, led by Yukihiro Inomata, a professor at the university in Kumamoto, Kumamoto Prefecture, the father has familial amyloid polyneuropathy
(FAP), a slowly progressive disease that can be fatal.
[ClickPress, Mon May 04 2015] Global Markets Direct's, 'Familial Amyloid Polyneuropathy
(Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H1 2015', provides an overview of the Familial Amyloid Polyneuropathy
(Transthyretin Amyloidosis, Corino de Andrade's Disease)'s therapeutic pipeline.
has earned a $1 million milestone payment from GlaxoSmithKline for the advancement of the Phase II/III study of ISIS-TTRRx in familial amyloid polyneuropathy
(FAP), a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.